Heinemann Klaas, Ruebig Alexander, Potthoff Peter, Schneider Hermann P G, Strelow Frank, Heinemann Lothar A J, Do Minh Thai
Center for Epidemiology & Health Research Berlin, Invalidenstr, 115, 10115 Berlin, Germany.
Health Qual Life Outcomes. 2004 Sep 2;2:45. doi: 10.1186/1477-7525-2-45.
This paper compiles data from different sources to get a first comprehensive picture of psychometric and other methodological characteristics of the Menopause Rating Scale (MRS) scale. The scale was designed and standardized as a self-administered scale to (a) to assess symptoms/complaints of aging women under different conditions, (b) to evaluate the severity of symptoms over time, and (c) to measure changes pre- and postmenopause replacement therapy. The scale became widespread used (available in 10 languages).
A large multinational survey (9 countries in 4 continents) from 2001/ 2002 is the basis for in depth analyses on reliability and validity of the MRS. Additional small convenience samples were used to get first impressions about test-retest reliability. The data were centrally analyzed. Data from a postmarketing HRT study were used to estimate discriminative validity.
Reliability measures (consistency and test-retest stability) were found to be good across countries, although the sample size for test-retest reliability was small.
The internal structure of the MRS across countries was astonishingly similar to conclude that the scale really measures the same phenomenon in symptomatic women. The sub-scores and total score correlations were high (0.7-0.9) but lower among the sub-scales (0.5-0.7). This however suggests that the subscales are not fully independent. Norm values from different populations were presented showing that a direct comparison between Europe and North America is possible, but caution recommended with comparisons of data from Latin America and Indonesia. But this will not affect intra-individual comparisons within clinical trials. The comparison with the Kupperman Index showed sufficiently good correlations, illustrating an adept criterion-oriented validity. The same is true for the comparison with the generic quality-of-life scale SF-36 where also a sufficiently close association has been shown.
The currently available methodological evidence points towards a high quality of the MRS scale to measure and to compare HRQoL of aging women in different regions and over time, it suggests a high reliability and high validity as far as the process of construct validation could be completed yet.
本文汇总了不同来源的数据,以初步全面了解更年期评定量表(MRS)的心理测量及其他方法学特征。该量表被设计为一种自填式量表,用于(a)评估处于不同状况下老年女性的症状/主诉,(b)评估症状随时间的严重程度,以及(c)衡量绝经前后替代疗法的变化。该量表已被广泛使用(有10种语言版本)。
2001/2002年来自4大洲9个国家的一项大型跨国调查是深入分析MRS可靠性和有效性的基础。还使用了其他小型便利样本以获得关于重测信度的初步印象。数据进行了集中分析。来自上市后激素替代疗法(HRT)研究的数据用于评估区分效度。
尽管重测信度的样本量较小,但各国的信度指标(一致性和重测稳定性)良好。
MRS在各国的内部结构惊人地相似,由此可以得出结论,该量表确实在有症状的女性中测量的是同一现象。各子量表得分与总分的相关性较高(0.7 - 0.9),但各子量表之间的相关性较低(0.5 - 0.7)。然而,这表明各子量表并非完全独立。给出了不同人群的常模值,表明欧洲和北美之间可以进行直接比较,但建议在比较拉丁美洲和印度尼西亚的数据时要谨慎。但这不会影响临床试验中的个体内比较。与库珀曼指数的比较显示出足够好的相关性,说明了良好的基于标准的效度。与通用生活质量量表SF - 36的比较也是如此,两者之间也显示出足够紧密的关联。
目前可得的方法学证据表明,MRS量表在测量和比较不同地区老年女性的健康相关生活质量(HRQoL)以及随时间的变化方面具有较高质量,就构建效度的过程而言,它显示出较高的信度和效度。